Our findings suggest that targeting the enzymatic catalytic center encoded by CHEK1 mRNA and circCHEK1_246aa is a promising therapeutic modality to target both MM cells and BM niche. This evidence concerns the gene CHEK1 and Miyoshi myopathy.